Condensed Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 33,163	$ 22,035	$ 93,173	$ 59,598
General and administrative	18,275	17,664	53,374	44,568
Total operating expenses	51,438	39,699	146,547	104,166
Loss from operations	(51,438)	(39,699)	(146,547)	(104,166)
Investment income, net	5,291	1,895	12,163	2,086
Other (expense) income, net	(3)	9	(22)	8
Net loss attributable to common stockholders	$ (46,150)	$ (37,795)	$ (134,406)	$ (102,072)
Net loss per share, basic	$ (0.54)	$ (0.53)	$ (1.73)	$ (1.61)
Net loss per share, diluted	$ (0.54)	$ (0.53)	$ (1.73)	$ (1.61)
Weighted-average number of common shares used in computing net loss per share, basic	85,952,501	71,008,993	77,682,237	63,522,774
Weighted-average number of common shares used in computing net loss per share, diluted	85,952,501	71,008,993	77,682,237	63,522,774